Be First to Access
The Next Generation
of Weight Loss
Retatrutide is showing 24% average weight loss in clinical trials—significantly more than semaglutide or tirzepatide. Join the waitlist to be notified the moment it becomes available.
Join the Waitlist
Get notified when retatrutide becomes available—plus exclusive early access pricing.
Why Join the Waitlist?
Early Access
Be among the first to access retatrutide when it receives FDA approval. Skip the waitlist that others will face.
Exclusive Pricing
Waitlist members get special launch pricing—potentially saving $100+ per month compared to general availability.
Latest Research
Stay informed with trial results, side effect data, and clinical updates as retatrutide moves toward approval.
Provider Access
Get connected with telehealth providers ready to prescribe retatrutide the day it's approved.
The Science Behind Retatrutide
Why researchers are calling it the most promising weight loss medication yet.
Average weight loss at 48 weeks in Phase 2 trials (12mg dose)—compared to 15% for tirzepatide and 12% for semaglutide.
Average pounds lost for a 240 lb person taking the highest dose—nearly double some current options.
GIP, GLP-1, and glucagon receptors—the first medication to target all three pathways simultaneously.
Currently in Phase 3 trials with over 10,000 participants. FDA decision expected 2027-2028.
Note: Retatrutide is investigational and not yet FDA-approved. Results from clinical trials may not reflect real-world outcomes. Always consult a healthcare provider before starting any weight loss medication.
Can't Wait for Retatrutide?
Start your weight loss journey today with proven GLP-1 medications.
Frequently Asked Questions
When will retatrutide be available?
Eli Lilly is targeting FDA approval in late 2027 or early 2028, pending successful Phase 3 trial results. Waitlist members will be notified immediately upon approval.
How much will retatrutide cost?
Exact pricing hasn't been announced, but expect it to be similar to or slightly higher than current GLP-1 medications ($200-400/month). Waitlist members may receive launch discounts.
Is retatrutide better than tirzepatide or semaglutide?
Clinical trials show retatrutide produces significantly more weight loss (24% vs 15% and 12%), but it's not yet approved. Head-to-head trials are ongoing.
What are the side effects?
Similar to other GLP-1 medications: nausea, vomiting, diarrhea, and constipation. Most side effects are mild-to-moderate and decrease over time. Always consult your doctor.
Will my email be shared or sold?
Never. We respect your privacy and will only send you retatrutide updates. Unsubscribe anytime with one click.
What happens after I join the waitlist?
You'll receive a welcome email, then periodic updates on trial progress, FDA milestones, and provider partnerships. When retatrutide is approved, you'll get priority access.
Don't Miss the Next Generation
Join 10,000+ people waiting for retatrutide. Be first in line.
Join the Waitlist